Search | Clinical Trials Finder

Conditions: Healthy
Interventions: meropenem-vaborbactam, Placebo, Moxifloxacin; Drug
Lead sponsor: Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.); Industry
Eligibility: 18 Years to 55 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza
Interventions: 3.75 µg H5N8 antigen plus full dose AS03A, 7.5 µg H5N8 antigen plus full dose AS03A, 15 µg H5N8 antigen plus full dose AS03A, 3.75 µg H5N8 antigen plus half dose AS03A, 7.5 µg H5N8 antigen plus half dose AS03A, 15 µg H5N8 antigen plus half dose AS03A, 3.75 µg H5N8 antigen plus MF59, 7.5 µg H5N8 antigen plus MF59, 15 µg H5N8 antigen plus MF59, 3.75 µg H5N1 antigen plus full dose AS03A, 7.5 µg H5N1 antigen plus full dose AS03A, 15 µg H5N1 antigen plus full dose AS03A, 3.75 µg H5N1 antigen plus MF59, 7.5 µg H5N1 antigen plus MF59, 15 µg H5N1 antigen plus MF59; Biological
Lead sponsor: Biomedical Advanced Research and Development Authority; Federal
Eligibility: 18 Years and older
Enrollment: 1,380 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 20
States / cities: Atlanta, Georgia • Savannah, Georgia • Oak Lawn, Illinois + 17 more

Conditions: Bacterial Infections
Interventions: Xeruborbactam, Cefiderocol, Xeruborbactam/Cefiderocol, Dextrose 5% in water; Drug
Lead sponsor: Qpex Biopharma, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Smallpox
Interventions: FD MVA-BN; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 1,129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 12
States / cities: Birmingham, Alabama • Melbourne, Florida • Peoria, Illinois + 8 more

Conditions: COVID-19
Interventions: Not listed
Lead sponsor: Pharm-Olam, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 6
States / cities: Boston, Massachusetts • Omaha, Nebraska • Syracuse, New York + 3 more

Conditions: Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
Interventions: Cohort C: bevacizumab, Cohort C: placebo; Drug
Lead sponsor: PPD Development, LP; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 41
States / cities: Birmingham, Alabama • Fresno, California • Long Beach, California + 34 more

Conditions: Cyanide Poisoning
Interventions: Stabilized Isoamyl Nitrite (SIAN); Drug
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Knoxville, Tennessee • Austin, Texas

Conditions: Avian Influenza
Interventions: aH5N1c, Placebo; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 18 Years and older
Enrollment: 3,196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 26
States / cities: Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 20 more

Conditions: Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral
Interventions: Low dose A/H2N3c + standard dose MF59, Intermediate dose A/H2N3c + standard dose MF59, High dose A/H2N3c + standard dose MF59, High dose A/H2N3c non-adjuvanted, Lowest dose A/H2N3c + high dose MF59, Low dose A/H2N3c + high dose MF59; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Rockville, Maryland • Lincoln, Nebraska • Omaha, Nebraska

Conditions: Acute Bacterial Skin and Skin Structure Infections
Interventions: ceftobiprole medocaril, vancomycin+aztreonam; Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years and older
Enrollment: 679 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 16
States / cities: Anaheim, California • Chula Vista, California • Fresno, California + 10 more

Conditions: Sepsis, COVID-19
Interventions: Not listed
Lead sponsor: Cytovale, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Sudan Virus Disease
Interventions: rVSVΔG-SUDV-GP, Placebo; Biological · Other
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 50 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Lenexa, Kansas • Boston, Massachusetts

Conditions: Covid19
Interventions: Infliximab, Abatacept, Remdesivir, cenicriviroc (closed to enrollment as of 3-Sep-2021); Drug
Lead sponsor: Daniel Benjamin; Other
Eligibility: 18 Years and older
Enrollment: 1,971 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 67
States / cities: Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 54 more

Conditions: E.Coli Infections, Bloodstream Infection
Interventions: SNIPR001, Placebo; Drug
Lead sponsor: SNIPR Biome Aps.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Pharmacokinetics, Healthy Volunteers
Interventions: ledaborbactam etzadroxil, ceftibuten; Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: COVID-19, Long COVID
Interventions: MouthLabTM; Device
Lead sponsor: Edith Nourse Rogers Memorial Veterans Hospital; Federal
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Bedford, Massachusetts

Conditions: Community-acquired Bacterial Pneumonia
Interventions: Solithromycin, Standard of Care; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 2 Months to 17 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 21
States / cities: Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 18 more

Conditions: Hepatic Impairment
Interventions: Fosmanogepix; Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Rialto, California • Tampa, Florida

Conditions: Safety
Interventions: MRX-8, Placebo; Drug
Lead sponsor: MicuRx; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: E Coli Infections, Allogenic Transplant Patients
Interventions: SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli, Placebo 10 mL; Biological · Other
Lead sponsor: SNIPR Biome Aps.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 8
States / cities: Duarte, California • San Francisco, California • Baltimore, Maryland + 5 more

Conditions: Burns
Interventions: RES (Regenerative Epidermal Suspension) prepared using the RECELL® Autologous Cell Harvesting Device, Mepilex® Ag Wound Dressing, Conventional autografting (only when indicated); Device · Combination Product · Procedure
Lead sponsor: Avita Medical; Industry
Eligibility: 1 Year to 16 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 9
States / cities: Phoenix, Arizona • Tampa, Florida • New Orleans, Louisiana + 6 more

Conditions: Dry Eye Disease
Interventions: INV-102, Vehicle; Drug
Lead sponsor: Invirsa, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Rush, New York

Conditions: SARS-CoV-2
Interventions: mRNA-1273, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30,415 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 100
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 79 more

Conditions: COVID-19, SARS-CoV2
Interventions: SAB-185, Normal Saline; Biological · Other
Lead sponsor: SAb Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Miami Beach, Florida • Omaha, Nebraska • Sioux Falls, South Dakota

Search by objective public record fields.

Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers

Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59

A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants

Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial

Specimen Collection Study From Coronavirus Disease 2019 (COVID-19) Vaccinated Adults and Adolescents

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab

Study of SIAN Nasal Spray in Healthy Adults

A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age

Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults

Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections

SQuISH-COVID: A Pilot Study

A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health

Immune Modulators for Treating COVID-19

A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects

Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Adults (18-55 Years)

Using Data From a Multisensor Rapid Health Assessment Device to Predict Decompensation in Long COVID (AIDI)

Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia

A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function.

Study of the Safety, Tolerability, and PK of MRX-8 Administered Intravenously to HVs in SAD and MAD Cohorts

Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant

RES® Prepared With RECELL® Compared to Standard of Care Dressings of Partial-thickness Burns in Ages 1-16 Years

Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19